Get the Stockscreener App
43.74
1.31%
-0.4288
Edgewise Therapeutics Inc stock is traded at $43.74, with a volume of 438.07K.
It is down -1.31% in the last 24 hours and up +9.64% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$44.17
Open:
$43.78
24h Volume:
438.07K
Relative Volume:
0.32
Market Cap:
$4.75B
Revenue:
-
Net Income/Loss:
$-176.01M
P/E Ratio:
-26.33
EPS:
-1.661
Net Cash Flow:
$-148.97M
1W Performance:
-2.22%
1M Performance:
+9.64%
6M Performance:
+44.92%
1Y Performance:
+208.07%
1-Day Range:
$42.59
$43.98
1-Week Range:
$41.98
$45.75
52-Week Range:
$13.53
$48.40
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
43.74 | 4.80B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
515.90 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.46 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.29 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
213.97 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd - marketbeat.com
44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP - marketbeat.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CSO Alan Russell sells $258k in stock - Investing.com
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock - Investing.com
Edgewise Therapeutics CSO Alan Russell sells $258k in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock - Investing.com
Edgewise Therapeutics general counsel Moore sells $219,822 in shares - Investing.com
Edgewise Therapeutics CBO sells $223k in shares for tax obligations - Investing.com
Edgewise Therapeutics general counsel Moore sells $219,822 in shares By Investing.com - Investing.com Australia
Joanne Donovan Sells 2,919 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock - marketbeat.com
Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in Stock - marketbeat.com
Edgewise Therapeutics (NASDAQ:EWTX) CEO Kevin Koch Sells 17,971 Shares of Stock - marketbeat.com
Edgewise Therapeutics President, CEO Sold Shares Worth Over $785K - TradingView
Edgewise Therapeutics (EWTX) GC nets RSU vesting, tax sales and new grants - Stock Titan
Edgewise Therapeutics (EWTX) grants CFO 24,375 RSUs and 48,750-share option - Stock Titan
Edgewise Therapeutics (EWTX) CSO gets 97,500-share equity awards, sells shares for taxes - Stock Titan
Edgewise Therapeutics (EWTX) CEO logs RSU vesting, sell-to-cover sales and 200,000 new options - Stock Titan
Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO - Stock Titan
RA Capital’s 7.8% Edgewise Therapeutics (EWTX) stake totals 8.39M shares - Stock Titan
Paradigm BioCapital reports 9.5% stake in Edgewise Therapeutics (EWTX) common stock - Stock Titan
Edgewise Therapeutics (EWTX): Baker Bros. discloses 3.4% ownership in Schedule 13G/A - Stock Titan
Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX - marketbeat.com
Edgewise Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC Expands Edgewise Therapeutics Inc (EWTX) Stake With 4.47 Million Share Purchase - GuruFocus
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by California State Teachers Retirement System - marketbeat.com
Price-Driven Insight from (EWTX) for Rule-Based Strategy - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
Edgewise Therapeutics Inc (EWTX) Stock News Today - TradingKey
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
FY2030 EPS Estimate for Edgewise Therapeutics Cut by Analyst - marketbeat.com
Edgewise Therapeutics (NASDAQ:EWTX) Posts Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Edgewise Therapeutics, Inc. Stock 12‑Month Price Target Raised to $50.46, Implies 12% Upside - TradingView
Edgewise ups R&D spending as pharma firm focuses on cardiovascular pipeline - bizwest.com
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Edgewise Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC discloses 5.1% Edgewise Therapeutics (EWTX) holding in Schedule 13G - Stock Titan
Edgewise Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Edgewise Therapeutics Q2 net loss widens on higher expenses - TradingView
Edgewise Therapeutics Q2 Net Loss Widens to $57.3 Million - Moomoo
Edgewise Therapeutics Q2 net loss widens to $57.3 million - Quiver Quantitative
Edgewise Therapeutics reports Q2 net loss $57.3M, cash $460.7M; announces sale of sevasemten - tradingview.com
Edgewise Therapeutics 2Q 2026: Net loss $57.3M, EPS ($0.53) — 10-Q Summary - TradingView
Edgewise Therapeutics (Nasdaq: EWTX) widens loss but nets $1,550 million Sevasemten Sale - Stock Titan
BRIEF-Edgewise Therapeutics Q2 Operating Income USD -61.943 Million - TradingView
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - TradingView
Edgewise Therapeutics earnings up next after HCM data, Servier deal By Investing.com - Investing.com Australia
Edgewise Therapeutics Gains as Investors Weigh Cash-rich Reset and Cardiovascular Pipeline Progress - moomoo.com
Edgewise Therapeutics gains as investors weigh cash-rich reset and cardiovascular pipeline progress - Quiver Quantitative
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO |
Aug 12 '26 |
Sale |
43.85 |
6,522 |
286,000 |
11,544 |
| Donovan Joanne M. | CMO |
Aug 13 '26 |
Sale |
43.41 |
2,919 |
126,704 |
8,625 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
12,812 |
0 |
37,367 |
| Russell Alan J | Chief Scientific Officer |
Aug 12 '26 |
Sale |
43.73 |
5,901 |
258,042 |
31,466 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Option Exercise |
0.00 |
12,499 |
0 |
22,713 |
| MOORE JOHN R | General Counsel |
Aug 12 '26 |
Sale |
43.82 |
5,016 |
219,823 |
17,697 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
13,281 |
0 |
36,926 |
| Derakhshan Behrad | Chief Business Officer |
Aug 12 '26 |
Sale |
43.81 |
5,100 |
223,424 |
31,826 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Option Exercise |
0.00 |
39,844 |
0 |
70,459 |
| KOCH KEVIN | President and CEO |
Aug 12 '26 |
Sale |
43.68 |
17,971 |
785,042 |
52,488 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):